Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...